

**REMARKS**

In the specification, the sequence listing has been revised to include two omitted residues from the C-terminal of SEQ ID NO:2.

Claims 1-3, 5-6, 11-19, 22, 23 and 25-27 remain in this application. Claims 4, 7-10, 20-21, 24 and 28-37 have been canceled at various times during the prior prosecution. Claim 27 is amended. The Examiner has acknowledged that claims 2, 3, 22 and 23 are directed to allowable subject matter. No new matter is added by the amendments.

Support for the amendments is found throughout the specification, such as in Figure 1, at page 3, line 30, page 4, lines 2, 6, 16, 30, 35, 39 and 41, page 5, lines 5, and page 6, line 4.

In view of the Examiner's earlier restriction requirement of Oct. 2, 2001, Applicants retain the right to present previously withdrawn and/or canceled claims in a divisional application.

**SUMMARY**

Claims 1-3, 5-6, 11-19, 22, 23 and 25-27 are pending in the application.


If in the opinion of the Examiner, a **telephone conference** would expedite the prosecution of the subject application, the Examiner is **strongly encouraged** to call the undersigned at the number indicated below.

In the unlikely event that this document is separated from the transmittal letter or if fees are required, applicants petition the Commissioner to authorize charging our Deposit Account 07-0630 for any fees required or credits due and any extensions of time necessary to maintain the pendency of this application.

Applicants respectfully request that a timely Notice of Allowance be issued in this case.

Respectfully submitted,  
GENENTECH, INC.

Date: **January 16, 2004**

By:   
Craig G. Svoboda  
Reg. No. 39,044  
Telephone No. (650) 225-1489